Related Experiment Video
Updated: Dec 11, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19
Michael Megaly1, Mattew Glogoza2
1Interventional cardiology fellow, Minneapolis Heart Institure, Abbott Northwestern Hospital, USA.
Insights
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) did not significantly alter mortality in COVID-19 patients. However, hypertensive patients on ACEIs/ARBs showed reduced mortality, warranting further investigation.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- The role of renin-angiotensin-aldosterone system inhibitors, including ACEIs and ARBs, in COVID-19 patients has been a subject of clinical debate.
- This meta-analysis aimed to synthesize existing evidence on the association between ACEI/ARB use and clinical outcomes in COVID-19.
Discussion:
- The pooled analysis of four observational studies (3,267 patients) indicated no significant difference in all-cause mortality between COVID-19 patients using ACEIs/ARBs and those not.
- A subgroup analysis focused on hypertensive patients revealed a statistically significant reduction in mortality risk for those treated with ACEIs/ARBs.
Key Insights:
- ACEI/ARB use in the general COVID-19 population is not associated with increased mortality.
- Hypertensive COVID-19 patients receiving ACEIs/ARBs may experience a survival benefit.
Outlook:
- Further research is necessary to confirm the protective effect of ACEIs/ARBs in hypertensive COVID-19 patients.
- Investigating the precise mechanisms behind this potential benefit is crucial for clinical practice guidelines.
Abstract:
The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients with Coronavirus 2019 (COVID-19) has been controversial. We performed a meta-analysis of all published studies that reported the outcomes of ACEIs/ARBs in patients with COVID-19. We included four observational studies (3,267 patients). The use of ACEIs/ARBs was associated with a similar risk of all-cause death (OR: 0.75, 95% CI [0.36, 1.57], p = 0.45). Sensitivity analysis including only hypertensive patients demonstrated a lower risk of death with ACEIs/ARBs use (OR: 0.57, 95% CI [0.32-0.98], p = 0.04). In conclusion, hypertensive patients with COVID-19 treated with ACEIs/ARBS have a lower mortality but further research is needed.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure V: Medical Management
Hormonal Regulation

